Peptide Research Collection Library
Explore the compound
Quick Facts
Mechanism of Action
TB-500 is a synthetic fragment related to thymosin beta-4 activity. Its mechanism is associated with actin binding, cell migration, angiogenesis, and tissue-repair signaling pathways.
Mechanism of Action: is associated with actin binding, cell migration, angiogenesis, and tissue-repair signaling pathways.
- Supports cell migration, wound repair, and tissue-regeneration pathways described for thymosin beta-4 [1].
- Associated with angiogenesis and extracellular-matrix remodeling in tissue-repair literature [1].
- Commonly discussed for soft-tissue, tendon, and muscle recovery support in research settings [1].
- Connects to inflammation-resolution and repair-signaling pathways indexed in PubMed [1].
Research Applications & Context
Community-reported protocol schedules.
Research Dosage Information
Reported research quantities and their source context. These are not recommendations, and source status varies.
Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.
Community report 1 · Weeks 1-2: 500 mcg Once daily. Weeks 1-2. Community report 1 · Weeks 3-4: 600 mcg Once daily. Weeks 3-4. Community report 1 · Weeks 5-8: 750 mcg Once daily. Weeks 5-8. Community report 1 · Weeks 9-12: 1000 mcg Once daily. Weeks 9-12. Community report 2 · Loading: ~2-2.5 mg 2 times weekly. Community report 2 · Maintenance: ~2-2.5 mg Once weekly.
| Phase | Reported Amount | Frequency | Draw Units | Cycle | Notes | Calculator |
|---|---|---|---|---|---|---|
| Community report 1 · Weeks 1-2 | 500 mcg | Once daily | Select a vial | Weeks 1-2 | Community-reported protocol. | |
| Community report 1 · Weeks 3-4 | 600 mcg | Once daily | Select a vial | Weeks 3-4 | Community-reported protocol. | |
| Community report 1 · Weeks 5-8 | 750 mcg | Once daily | Select a vial | Weeks 5-8 | Community-reported protocol. | |
| Community report 1 · Weeks 9-12 | 1000 mcg | Once daily | Select a vial | Weeks 9-12 | Community-reported protocol. | |
| Community report 2 · Loading | ~2-2.5 mg | 2 times weekly | Select a vial | Community-reported protocol. | ||
| Community report 2 · Maintenance | ~2-2.5 mg | Once weekly | Select a vial | Community-reported protocol. |
Dosing Protocol & Schedule
Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.
| Period | Research Dose | Frequency | Total Injections | Total amount | Volume per entry | U-100 equivalent |
|---|
Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.
Plan a Regimen Schedule
Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.
Reconstitution Calculator
Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.
Reconstitution Reference Chart
Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.
| Example volume | Calculated concentration | Calculator |
|---|---|---|
| 1 mL | — | |
| 2 mL | — | |
| 3 mL | — | |
| 4 mL | — | |
| 5 mL | — |
Choose a compatible dry vial to see reference concentrations.
Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.
Supplies Needed — Estimate
Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.
Select a compatible vial and volume below to view quantities.
Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.
Published References (0 identified)
A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.
Research indexes & other source links
Searches, registries and unverified source records are discovery resources, not verified published studies.
- PubMed.gov biomedical literature: TB500 (Thymosin B4 Acetate) View source ↗ PubMed index/search · Source link recorded; claim verification separate
- ClinicalTrials.gov study registry: TB500 (Thymosin B4 Acetate) View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
- NIH/NCBI all-databases search: TB500 (Thymosin B4 Acetate) View source ↗ NCBI database/search · Source link recorded; claim verification separate
- PubChem / NIH compound record search: TB500 (Thymosin B4 Acetate) View source ↗ PubChem database/search · Source link recorded; claim verification separate
